Currently, there is ongoing debate on the prognostic significance of FoxP3+Tregs in individuals diagnosed with digestive tract malignancies.[22] FoxP3+Tregs have been found to have contrasting effects on various digestive system tumors, such as liver cancer and gastric cancer, where they are considered unfavorable prognostic factors.[23] However, in the case of colorectal cancer, the results are contrary to this trend.[24] This discrepancy may be attributed to the inhibitory effects of FoxP3+Tregs on inflammation and immune response, which are caused by the invasion of intestinal bacteria. This evidence concerns the gene FOXP3 and gastric cancer.